ABcann Extends Agreement With Medical Cannabis Pioneer
OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) — ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that Raphael Mechoulam has agreed to extend his role as an advisor to the Company.
Mechoulam is an Israeli Organic Chemist, and a professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the “Father of Marijuana Research.”
Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain’s first endogenous cannabinoid, Anandamide, in 1992.
“Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann.
I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies.
Professor Raphael Mechoulam
“The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann.